SCICLONE PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements Of Cash Flows

In millions of USD, except per-share amounts

	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012
Operating activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Non-cash expense related to stock-based compensation
Non-cash escrow share settlement
Provision for doubtful accounts
Provision for expiring inventory
Depreciation and amortization
Intangible asset impairment
Loss on maturity of available-for-sale investment
Change in fair value of contingent consideration
Loss on disposal of fixed assets
Change in fair value of contingent consideration (Note 3)
Deferred income taxes
Unrealized foreign exchange loss
Changes in operating assets and liabilities:
Accounts receivable, net
Inventories
Prepaid expenses and other assets
Restricted cash in escrow for SEC settlement (Note 15)
Accounts payable
Accrued and other current liabilities
Deferred revenue
Deferred revenue
Other long-term liabilities

Net cash provided by operating activities
Investing activities:
Purchases of available-for-sale investments
Proceeds from the maturity of available-for-sale securities
Proceeds from the maturity of available-for-sale securities or short-term investments
Investment in available-for-sale security of third party (Note 5)
Loans to third party (Note 6)
Proceeds from the sale of short-term investments
Purchases of property and equipment
Net cash used in investing activities

Financing activities:
Repurchase of common stock including commissions
Proceeds from borrowing on short-term loan
Repayment of credit facilities
Proceeds from borrowing on credit facilities
Decrease in restricted cash related to loan facility
Proceeds related to issuances of common stock, net
Net cash provided by (used in) financing activities

Effect of exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosure of cash flow information:
Net income taxes paid related to foreign operations
Interest and unused line fees paid related to borrowings
Release of restricted cash in escrow for SEC settlement

Comments